Soligenix obtains exclusive option for Phase 2/3-ready topical Pentoxifylline in Behçet's Disease

SOLIGENIX, INC.

Exclusive option agreement with Silk Road Therapeutics to acquire topical Pentoxifylline for mucocutaneous ulcers in Behçet's Disease.
BD affects ~18,000 US, 80,000 EU patients; orphan disease with no cure, current treatments limited.
Phase 2 trial showed 83% of PTX patients had ulcer shrinkage by Day 2 vs 19% colchicine (p<0.0001).
By Day 4, 72% on PTX had undetectable ulcer vs 29% colchicine; no serious adverse events.
Program is Phase 2/3-ready; Soligenix plans FDA discussions on trial design.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.